The Stanford lung group has finally entered the worldwide digital age! (No need to comment about the irony) #ASCO19

“Biostatisication”....saw this in a protocol. Is this what you call the biostatistician who is on a permanent vacation?

Wonderful presentations in Presidential symposium IASLC #wclc19 on screening. Wonderful to see strategies to better individualize screening in development. Lung cancer screening saves lives!

Connecting with old friends and meeting new ones while strategizing our fight against thoracic cancers at the #EAonc fall meeting. Amazing leadership by Suresh S. Ramalingam, MD, FASCO Heather Wakelee Christine Lovly, MD, PhD ! #LCSM

From the mountains ⛰ to the ocean shore 🌊, From urban cities to rural towns, From the aged to the young, regardless of race, color, or creed ANY ONE WITH LUNGS CAN GET LUNG CANCER. Spreading awareness even in Lake Tahoe. #ResearchMatters

I am pleased to announce that SCI member Joel Neal has been named the new Medical Director for our Cancer Clinical Trials Office. This leadership role provides critical oversight for day-to-day operations of the cancer clinical research enterprise. Joel W. Neal, MD, PhD Heather Wakelee

Steven Artandi, MD, PhD Heather Wakelee Looking forward to guiding our fantastic cancer clinical trials organization together with our new Deputy SCI Director, Heather Wakelee !

#OncoAlert It has been my practice to continue osimertinib in #EGFR NSCLC at progression when starting chemo, particularly in the setting of CNS metastases (despite IMPRESS). This retrospective report outlines our experience with safety and efficacy. #LCSM clinical-lung-cancer.com/article/S1525-…

I think the main difference with IMPRESS is the role of osi in maintaining CNS control. We need prospective data but this retrospective report is a helpful start. Thanks to collaborators Drs. Maya White Zosia Piotrowska Lecia Sequist, MD, MPH Heather Wakelee Daniel Hausrath Joel W. Neal, MD, PhD #LCSM

Figuring out IO approaches for patients that experience disease progression on checkpoint inhibitors remains one of the most critical questions in modern oncology. This trial presented by Joel W. Neal, MD, PhD evaluates the multikinase inhibitor cabozantinib with atezo here #WCLC20 #LCSM

.Joel W. Neal, MD, PhD, of Stanford Medicine, discusses the emergence of targets such as HER2 exon 20 insertions and amplification, MET amplification, and NRG1 fusions. #lcsm ow.ly/lt2B50IleR1

Congratulations to the chairs and presenters for a perfect start to the Lung Cancer Metastatic Oral session at #ASCO22 Charu Aggarwal, MD, MPH, FASCO Sukhmani (Suki) Padda MD Alex Spira, M.D. Greg Durm

i am